Want to see ABOS full AI Analyst Report?
Top Page
Acumen Pharmaceuticals
(NASDAQ:ABOS)
Select Model
Select Model
Rating:51Neutral
Price Target:
$3.00
▲(40.85% Upside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance (no revenue, large losses and sustained cash burn with rising leverage and shrinking equity). Technicals are comparatively supportive with the stock trading above major moving averages and a positive MACD, but stretched momentum readings temper that benefit. The earnings call adds moderate support from late-2026 clinical catalysts and encouraging program updates, while valuation remains constrained by ongoing losses and no dividend.
Positive Factors
Phase II clinical catalyst
The late-2026 Phase II readout is a material value driver because it can validate sabirnetug’s clinical efficacy and target approach. Positive results could support further development, partnering interest and a broader Alzheimer’s treatment opportunity.
Negative Factors
Pre-revenue operating model
Acumen has no commercial revenue to offset research and development costs, leaving its financial profile dependent on clinical progress and external capital. Continued losses limit operating resilience and make profitability contingent on successful product development.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase II clinical catalyst
The late-2026 Phase II readout is a material value driver because it can validate sabirnetug’s clinical efficacy and target approach. Positive results could support further development, partnering interest and a broader Alzheimer’s treatment opportunity.
Read all positive factors
Acumen Pharmaceuticals (ABOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$228.52M
Dividend YieldN/A
Average Volume (3M)580.72K
Price to Earnings (P/E)―
Beta (1Y)2.42
Revenue GrowthN/A
EPS Growth27.94%
CountryUS
Employees61
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.64
Shares Outstanding72,317,280
10 Day Avg. Volume376,503
30 Day Avg. Volume580,724
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.81
Price to Sales (P/S)0.00
P/FCF Ratio-1.11
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside181.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.53
Revenue Forecast (FY)N/A
Acumen Pharmaceuticals Business Overview & Revenue Model
Company Description
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Acumen Pharmaceuticals does not have publicly established, recurring revenue from commercial product sales; its lead program remains in clinical development. Accordingly, its operations have primarily...
Acumen Pharmaceuticals Earnings Call Summary
Earnings Call Date:Aug 12, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call highlighted meaningful scientific and programmatic progress: a high-impact Phase II readout expected late 2026, strong Phase I target engagement, and a differentiated EBD program with compelling non-human primate brain exposures (up to 40x). Financially, the company is managing costs (R&D down versus prior year; G&A stable) but has a finite cash runway (approximately into early 2027) and reported a sizable quarterly net loss, which creates funding risk ahead of mid-2027 IND plans. Operational and design uncertainties (powering details for two-dose analysis, selection of EBD clinical lead, clinical start strategy) were noted but do not outweigh the near-term scientific catalysts and preclinical wins. Overall the tone is cautiously optimistic pending the upcoming ALTITUDE-AD topline.Positive Updates
Upcoming Phase II ALTITUDE-AD Topline Readout
Topline readout from the Phase II ALTITUDE-AD study of sabirnetug expected late 2026. Study designed to detect a statistically significant difference on the iADRS primary endpoint after 18 months versus placebo and will report key secondary measures including CDR-SB, safety (adverse events and ARIA rates), and fluid/imaging biomarkers. Two active dose levels being evaluated: 35 mg/kg and 50 mg/kg.
Negative Updates
Limited Cash Runway Beyond Near Term
Cash balance of $110.2M is expected to fund operations into early 2027, creating potential financing risk to support programs (including an IND targeted mid-2027 for the EBD franchise) if additional capital is not secured.
Read all updates
Q2-2026 Updates
Positive
Negative
Upcoming Phase II ALTITUDE-AD Topline Readout
Topline readout from the Phase II ALTITUDE-AD study of sabirnetug expected late 2026. Study designed to detect a statistically significant difference on the iADRS primary endpoint after 18 months versus placebo and will report key secondary measures including CDR-SB, safety (adverse events and ARIA rates), and fluid/imaging biomarkers. Two active dose levels being evaluated: 35 mg/kg and 50 mg/kg.
Read all positive updates
Company Guidance
Acumen reiterated that the Phase II ALTITUDE‑AD topline readout is expected late 2026 and will report the 18‑month primary clinical efficacy endpoint (iADRS, powered to detect a statistically significant difference), key secondary CDR‑SB results, safety (adverse events and ARIA rates) and fluid and imaging biomarkers across two active doses (35 mg/kg and 50 mg/kg) versus placebo; Phase I showed target engagement and biomarker changes as early as 3 months and a 12‑month open‑label extension is ongoing. Financially, Q2 FY2026 R&D expense was $27.8M, G&A $4.7M, loss from operations $32.6M, net loss $32.7M, and cash and marketable securities totaled $110.2M, which management expects will fund operations into early 2027. They nominated two EBD candidates (ACU301, ACU401), reported up to 40‑fold greater frontal cortex exposure for ACU401 in non‑human primates, plan an IND filing for the lead EBD candidate in mid‑2027, will hold a virtual IR Day on September 16, 2026, and noted they may reduce public engagement in Q4 ahead of the readout.Acumen Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -46.00K | 0.00 | 0.00 | 0.00 | -169.00K | -12.30M |
| EBITDA | -100.40M | -116.93M | -98.08M | -51.61M | -42.69M | -100.60M |
| Net Income | -105.04M | -121.33M | -102.33M | -52.37M | -42.86M | -100.61M |
Balance Sheet | ||||||
| Total Assets | 116.01M | 122.83M | 238.99M | 310.13M | 196.59M | 230.33M |
| Cash, Cash Equivalents and Short-Term Investments | 110.20M | 116.86M | 171.56M | 243.52M | 177.60M | 194.24M |
| Total Debt | 31.57M | 31.31M | 29.70M | 28.49M | 105.00K | 0.00 |
| Total Liabilities | 58.74M | 52.40M | 57.18M | 43.15M | 7.81M | 5.15M |
| Stockholders Equity | 57.26M | 70.43M | 181.82M | 266.97M | 188.78M | 225.18M |
Cash Flow | ||||||
| Free Cash Flow | -91.79M | -115.63M | -86.23M | -43.09M | -35.31M | -18.00M |
| Operating Cash Flow | -91.79M | -115.54M | -86.22M | -43.06M | -35.15M | -17.96M |
| Investing Cash Flow | 78.95M | 133.93M | 48.03M | -171.67M | 39.19M | -104.12M |
| Financing Cash Flow | 35.47M | -34.00K | 6.93M | 151.75M | 3.91M | 200.47M |
Acumen Pharmaceuticals Technical Analysis
Positive
2.13
Price Trends
2.44
Positive
2.47
Positive
2.39
Positive
Market Momentum
0.19
Negative
77.82
Negative
90.83
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABOS, the sentiment is Positive. The current price of 2.13 is below the 20-day moving average (MA) of 2.49, below the 50-day MA of 2.44, and below the 200-day MA of 2.39, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 77.82 is Negative, neither overbought nor oversold. The STOCH value of 90.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABOS.
Acumen Pharmaceuticals Risk Analysis
Acumen Pharmaceuticals disclosed 85 risk factors in its most recent earnings report. Acumen Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acumen Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $333.49M | -5.03 | -42.80% | ― | ― | 59.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $228.52M | -1.93 | -136.27% | ― | ― | 27.94% | |
45 Neutral | $281.97M | -0.58 | 187.62% | ― | -8.79% | -195.46% | |
43 Neutral | $52.83M | -0.86 | -108.72% | ― | 2.15% | 17.34% | |
31 Underperform | $10.83M | -0.14 | -133.02% | ― | ― | ― |
* Healthcare Sector Average
ABOS
Acumen Pharmaceuticals
3.16
1.65
109.27%
VTGN
VistaGen Therapeutics
0.24
-2.79
-91.95%
IKT
Inhibikase Therapeutics
2.39
0.63
35.80%
SRZN
Surrozen
23.99
12.49
108.61%
TCRX
TScan Therapeutics
0.78
-1.12
-59.00%
Acumen Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial Disclosures
Acumen Pharmaceuticals Reports Q2 Results, Advances Alzheimer’s Programs
Positive
Aug 12, 2026
On August 12, 2026, Acumen Pharmaceuticals reported second-quarter 2026 financial results and business highlights, and posted an updated corporate presentation reflecting a cash, cash equivalents and marketable securities balance of $110.2 million...
Business Operations and StrategyProduct-Related Announcements
Acumen Advances Enhanced Brain Delivery Alzheimer’s Drug Candidates
Positive
Jun 16, 2026
On June 16, 2026, Acumen Pharmaceuticals announced it had nominated two Enhanced Brain Delivery development candidates, ACU301 and ACU401, for Alzheimer’s disease under its collaboration with JCR Pharmaceuticals and exercised its option to l...
Executive/Board ChangesShareholder Meetings
Acumen Stockholders Approve Directors and Equity Incentive Plan
Positive
Jun 3, 2026
On June 3, 2026, Acumen Pharmaceuticals, Inc. held its 2026 annual meeting of stockholders, with about 79% of the 72.2 million outstanding shares present or represented by proxy. Stockholders elected three Class II directors, George Golumbeski, Ph...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.